

## **Vaccination coverage trends in European Union from 1980 to 2020: A joinpoint Regression Analysis**

Causio FA<sup>1</sup>, Villani L<sup>2</sup>, Mariani M<sup>1</sup>, Pastorino R<sup>1</sup>, De Waure C<sup>3</sup>, Ricciardi W<sup>1</sup>, Boccia S<sup>1</sup>.

### **Affiliations**

<sup>1</sup> Section of Hygiene, University Department of Life Sciences and Public Health — Università Cattolica del Sacro Cuore, Rome, Italy

<sup>2</sup> UniCamillus International University of Health and Medical Sciences, Rome, Italy

<sup>3</sup> Department of Medicine and Surgery, University of Perugia, Perugia, Italy

### **Abstract**

Vaccination coverage trends across European Union (EU) countries have shown concerning variations in recent years. This study aims to analyze vaccination coverage trends for seven key vaccinations across all EU member states from 1980 to 2020. Data from the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) dataset were analyzed using joinpoint regression models to identify significant changes in vaccination coverage trends. Seven vaccination indicators were examined: DTP-3, HEPB-3, HIB-3, MCV-1, PCV-3, POL-3, and RCV-1. Trends were categorized as positive or negative and significant or not significant, based on Annual Percent Change (APC) calculations. Analysis of 180 joinpoint regressions revealed a predominantly downward trend in vaccination coverage across the EU. 51.7% showed negative performance, while only 37.8% showed positive performance. Only 8 countries (29.6%) demonstrated increased coverage in at least four indicators, while 14 countries (51.8%) showed reduced coverage. The study reveals a concerning decline in vaccination coverage across most EU countries. The findings suggest that mandatory vaccination policies may contribute to maintaining higher coverage rates, though multiple factors influence vaccination uptake, including political, social, and educational determinants.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## Introduction

Vaccinations represent one of the most successful and cost-effective public health interventions and have led to the eradication, elimination, and control of many infectious diseases in the last few decades (1,2). The relevance of vaccination is testified by its contribution to eradicating smallpox in 1980, while nowadays it is a key tool for eliminating wild polio (3,4). Vaccinations have reduced the burden of diseases such as tetanus, whooping cough, pneumonia, measles, influenza, and diphtheria, annually preventing 4-5 million deaths worldwide (5). In addition to the important health benefits, vaccination is one of the most cost-effective interventions, reducing direct and indirect costs related to infectious diseases (6,7).

In recent years, however, vaccine hesitancy, defined as a delay in acceptance or outright refusal despite the availability of vaccination services (8), has gained momentum, especially due to misinformation and miscommunication at both political and scientific levels. This phenomenon affects countries worldwide differently and unevenly, and depends on several social, political, educational, economic, behavioural, and health factors (8). In this context, the increase in the hesitant population has led to a reduction in vaccine coverage, with vaccine-preventable diseases re-emerging, even in high-income European Union (EU) countries (9). To face this situation, many countries adopted several measures, so policies in Europe are highly variable across and within countries with some of them recommending some vaccines and some adopting vaccination mandates (10–12). In particular, 14 EU countries (Belgium, Bulgaria, Croatia, Czechia, France, Germany, Greece, Latvia, Hungary, Italy, Malta, Poland, Slovakia and Slovenia) have established at least one mandatory vaccination for school entry, with differences in terms of modalities, timing, and the number of vaccines (12). For example, in Belgium, the only mandatory vaccination is against polio, in place since 1967 (11). On the other hand, in Italy, the number of mandatory vaccinations increased in 2017 from four to ten (pertussis, *Haemophilus influenzae* type B, measles, mumps, rubella, and varicella were added to diphtheria, polio, tetanus, and hepatitis B) (13). Similarly, in France, a law of 2018 established eleven mandatory vaccinations, against diphtheria, tetanus, pertussis, polio, hepatitis B, *Haemophilus influenzae* type B, measles, mumps, rubella, meningococcal C, and pneumococcal infection (14). Other countries, however, have maintained an approach emphasizing personal freedom and approaches empowering citizens, encouraging them to take the best decision. As an example, Sweden when experienced limited outbreaks of measles and rubella occurring after spreading from people infected abroad in 2013 (15), they introduced new vaccine policies offering at-risk groups tailored immunization programmes and conducted pilot projects investigating underserved

populations with low vaccination coverages, showing a need for increased knowledge and understanding for the diseases and vaccinations included in national vaccination programmes.

Currently, information on population coverage against several preventable communicable diseases at country level is available from different sources, such as international organisations, Ministries of Health, national institutions, and independent research centres. However, to date, a systematic synthesis of European vaccination coverage trends has not been developed. Nevertheless, analysis of this kind of data is crucial to controlling the evolution of infectious diseases and also to assessing the effectiveness of adopted targeted policies at the national and international levels (16–18). Evaluating trends in vaccination coverage allows for the provision of scientific evidence for policymakers to implement effective and targeted prevention strategies. In this context, our study aims to describe the trend of vaccination coverage for seven vaccinations from 1980 to 2020 across EU countries, and to identify positive, negative, or stationary evolutions for both the single vaccination and the single country.

## **Methods**

### *Data source*

We extracted data about vaccination coverage from the publicly available WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) dataset, based on data officially reported to the organizations by Member States every year, as of July 2021 (19–21). We included all 27 EU countries in our analysis. We considered the period from the first year available – 1980 (or more recently if data were unavailable) to 2020 (or 2019 when no data were available for 2020). Based on the availability of data, we considered coverage indicators referring to seven vaccinations scheduled during the first year of life to prevent nine vaccine-preventable diseases. In particular, we selected: the percentage of one-year-olds who had received all three doses of the combined diphtheria, tetanus toxoid, and pertussis vaccine (DTP-3); the percentage of one-year-olds who had received three doses of hepatitis B vaccine (HEPB-3); the percentage of one-year-olds who had received three doses of Haemophilus influenzae type B vaccine (HIB-3); the percentage of one-year-olds who had received the first dose of measles-containing vaccine (MCV-1); the percentage of one-year-olds who had received three doses of pneumococcal conjugate vaccine (PCV-3); the percentage of one-year-olds who had received three doses of polio vaccine (POL-3); the percentage of one-year-olds who had received at least one dose of rubella-containing vaccine (RCV-1) (22). Data on immunization recommendation were assessed with the European Centre for Disease Prevention and Control's Vaccine scheduler platform. (23)

### *Statistical analysis*

In order to assess changes in vaccination coverage trends across EU countries, we used the joinpoint regression model. Joinpoint regression is a tool for analysing changes in trends over time and, for this reason, it is used in many scientific domains (24–26). Indeed, this model allows for identifying a point (“joinpoint”) when a change in a parameter occurs within the time series. In our study, we conducted a trend analysis for each coverage indicator for all countries. In particular, we considered the year as the independent variable and the vaccination coverage indicator as the dependent variable, expressed as a percentage, while the results were sorted by country. Following previous studies (27) on this topic, we assumed that error variance was constant and that population sizes have not influenced the vaccination coverages over time.

Moreover, the joinpoint model allows for estimating an Annual Percent Change (APC) in vaccination coverage, reflecting an increase or decrease over time. For each vaccination, the presence of any joinpoint (the software ranges from a minimum of 0 to a maximum of 5 joinpoints) expressed significant changes in the APC trend. We considered the APC significant when  $p < 0.05$ . The analysis was performed using Joinpoint Trend Analysis Software 4.9.0.0 – Desktop Version, available from the Surveillance Research Program of the US National Cancer Institute (28).

### *Reporting of results*

The last two trends that occurred in the time series were considered for each coverage indicator. In particular, for reasons of consistency, we called the second-last trend “trend A”, accounting for the period between the second-last and the last joinpoints, and the last trend “trend B”, accounting for the period after the last joinpoint. Trends A and B are marked for clarity in graph xxx. Based on the significance of the APC, each trend was labelled as follows compared with vaccination coverage: significant increase, significant decrease, non-significant increase, and non-significant decrease. The trend was defined as stationary if no change occurred during the entire period. Variation between trends A and B was considered when defining confirmation or reversal of the trend for each coverage indicator in each country.




Figure 1. Sample graph displaying the last and second-last joinpoints, as well as trend A-B

In addition, based on the changes between trend A and trend B, two possible evolutions were considered: a positive evolution of coverage if trend A stayed significantly positive in trend B, if trend A (of any other type) became significantly positive, or if a significantly negative trend A lost significance in trend B. Conversely, a negative vaccination coverage trend resulted from trend A remaining significantly negative in trend B, trend A (of any type) becoming significantly negative, and significantly positive trend A losing significance in trend B. As for vaccination coverages without a joinpoint (i.e., those with one single trend), we considered a positive performance when the trend was positive (significant or non-significant) and negative when the trend was negative (significant or even non-significant).

Eventually, to identify which EU countries presented an overall improving or worsening trend in vaccination coverage, we considered those countries where a significant variation was observed in trend B compared to trend A in at least four of the seven indicators included (>50%). This method allowed us to evaluate in which countries there was an overall positive or negative evolution of vaccination coverage.

## Results

We ran 180 joinpoint regressions, resulting from the seven considered indicators across the 27 EU countries considered in the study, except for those vaccinations whose data were missing in the database, i.e. HEPB-3 in Denmark, Finland, Hungary and Slovenia, and PCV-3 in Austria, Croatia, Czech Republic, Estonia, and Malta. In addition to displaying the performed analyses within the manuscript's core, the authors listed all the raw analyses resulting from the joinpoint models in Table S1 in the Supplementary Material. At least one joinpoint was observed in 144 cases, while in 36 cases, there was a unique single trend (Table 1 and Table 2). Considering the trends with at least one joinpoint, 39 out of 144 (27.1%) showed a significantly positive trend B (22 confirmed positive and 17 becoming positive) and 49 (34%) a significantly negative trend B (34 confirmed and 15 becoming negative) (Table 1). Instead, out of 36 trends without a joinpoint, 13 (36.1%) and 5 (13.9%) were significantly positive and significantly negative, respectively, while 8 (22.2%) were positive and 3 (8.4%) were negative, but not significantly (Table 2). Overall, 93 (51.7%) and 68 (37.8%) trends showed a negative and positive performance, respectively, while in 19 cases (10.5%) no changes were observed. Full details regarding each indicator are available in Table 3.

### *DTP-3*

Overall, 21 (77.8%) and 6 countries (22.2%) reported at least one joinpoint and one single trend, respectively (Table 1 and Table 2). Considering both trends with and without a joinpoint, a reduction in vaccination coverage was predominantly observed for the DTP-3 indicator (14 countries, 51.8%) (Figure 1). Instead, 10 countries (37.1%) showed an increasing coverage, while in 3 cases (Belgium, Hungary, and Latvia), no significant trends were reported (11.1%). In detail, Austria, Poland, Romania, and Slovenia (14.8%) showed a significantly negative reversal of the trend (significantly positive trend A became significantly negative in trend B), while in Estonia, Netherlands, and Sweden (11.1%), the non-significantly positive trend A became significantly negative in trend B. A significantly positive trend A lost significance in trend B in Cyprus, France, Ireland, Luxembourg, Germany, and Latvia (22.2%), while it became negative (non-significant) in Germany and Italy (7.4%). Finally, Bulgaria showed a single significantly negative trend (3.7%).

Considering the positive trends, trend B was significantly positive in Portugal and Slovakia (7.4%), while only in Denmark (3.7%) the significantly negative trend A reversed into a significantly positive trend B. In Croatia, Czechia, and Finland (11.1%), trend A reversed from significantly negative to a non-significantly positive trend B. Greece, Malta, and Spain showed a single significantly positive trend (11.1%).

### *HEPB-3*

For this indicator, we observed at least one joinpoint in 20 countries (74.1%), while in 3 countries (11.1%), the trend did not show any change. (Table 1 and Table 2). Data were missing for Denmark, Finland, Hungary, and Slovenia (14.8%). Also, out of 23 regressions, we mainly observed a negative evolution (15 countries, 65.2%) rather than a positive one (7 countries, 30.4%) (Figure 1). No significant trends were reported in Italy (3.7%). In particular, in Austria, Ireland, Latvia, and Lithuania (17.4%), trend A reversed from significantly positive to significantly negative in trend B, while in Croatia and Romania (8.7%), a non-significant positive trend A reversed to a significantly negative trend B. Moreover, the positive trend A lost significance in 8 countries (34.8%) (Cyprus, France, Greece, Netherlands, Portugal, Sweden, Luxembourg, and Spain). Finally, Estonia reported a single significantly negative trend (4.3%). On the other hand, Belgium, Germany, and Poland (13.0%) maintained a significantly positive trend B, while in Czechia and Slovakia (8.7%), the significantly negative trend A shifted to a significantly positive trend B. Finally, Malta (4.3%) reported a single significantly positive trend.

### *HIB-3*

Overall, 24 (88.9%) and 3 countries (11.1%) reported at least one joinpoint and a single trend, respectively, with a majority of negative performances (Table 1 and Table 2). In particular, we observed a negative evolution of the coverage in 17 countries (63%) and a positive one in 7 countries (25.9%) (Figure 1). In 3 countries (11.1%), no significant increasing or decreasing trend was observed. In detail, the significantly positive trend A became significantly negative in trend B in Croatia, Germany, Ireland, Italy, Netherlands, Slovakia, and Sweden (25.9%), while it lost its significance in Belgium, Cyprus, Latvia, Lithuania, France, Malta, and Spain (25.9%). Finally, the non-significantly positive trend A reversed to a significantly negative trend B in Austria (3.7%). On the contrary, trend B remained significantly positive in Estonia, Greece, Poland, and Portugal (14.8%), while in Denmark (3.7%), the significantly negative trend A shifted to a significantly positive trend B. Moreover, an increase in coverage was observed in Finland and Slovenia (7.4%), where the significantly negative trend A became non-significantly positive in trend B.

### *MCV-1*

Overall, 23 (85.2%) and 4 countries (14.8%) reported at least one joinpoint and a single trend, respectively, with a majority of positive evolutions (Table 1 and Table 2). Indeed, the MCV-1 indicator showed an increasing and decreasing trend in 14 (51.9%) and 10 (37%) countries, respectively. In 3 countries, no significant variations were observed (11.1%) (Figure 1). We observed a significantly positive trend A followed by a significantly positive trend B in Ireland, Italy, Luxembourg, Spain, and Sweden (18.5%). Moreover, the significantly negative trend A became

significantly positive in trend B in Denmark and Latvia (7.4%), while it lost negative significance in Croatia (3.7%). In Portugal, Austria, and Malta (11.1%), the non-significant trend A reversed to a significantly positive trend B. Finally, Belgium and Greece reported one single significantly positive trend (7.4%). On the other hand, the significantly positive trend A became significantly negative in trend B in Bulgaria, Czechia, Estonia, Poland, and Romania (18.5%), while in Finland and Latvia, the non-significantly positive trend A became significantly negative (7.4%). Moreover, the significantly positive trend A lost significance in Cyprus, France, and Germany (11.1%).

### *PCV-3*

Overall, 8 (36.4%) and 14 countries (51.8%) reported at least one joinpoint and a single trend, respectively, while for 5 countries (18.6%) data were not available ((Table 1 and Table 2). Thus, out of 22 countries, 10 (45.4%) showed a significant increase in coverage, while 8 (36.4%) reported a negative evolution (Figure 1). Finally, no changes were observed in 4 countries (18.2%). Trend B remained significantly positive in Italy (4.5%), while in Slovakia (4.5%), the significantly negative trend A became significantly positive in trend B. Belgium, Denmark, Hungary, France, and Slovenia (22.7%) reported a single significantly positive trend. On the contrary, the significantly positive trend A shifted to a significantly negative trend B in Bulgaria, Ireland, Germany, and Sweden (18.2%), while it lost the positive significance in Luxembourg (4.5%). Finally, Finland and the Netherlands (9.1%) reported a single significantly negative trend.

### *POL-3*

Overall, 24 (88.9%) and 3 countries (11.1%) reported at least one joinpoint and a single trend, respectively (Table 1 and Table 2). A decrease in coverage was registered in 19 countries (70.4%), while in only 8 countries (29.6%) we observed an increase in POL-3 coverage. In one country (Latvia), no significant trend was observed (3.7%) (Figure 1). In particular, the significantly positive trend A became significantly negative in trend B in Austria, Estonia, France, Romania, Slovenia, and Sweden (22.2%), while it remained significantly negative in Poland. The non-significantly positive trend A became significantly negative in trend B in Finland, Italy, and the Netherlands (11.1%). Moreover, trend A lost positive significance in Belgium, Germany, Ireland, Greece, Latvia, Luxembourg, Malta, Poland, and Spain (33.3%). Finally, Bulgaria (3.7%) reported a single significantly negative trend. On the contrary, trend B was confirmed significantly positive in Cyprus and Portugal (7.4%), while in Czechia, Denmark, and Slovakia (11.1%) the significantly negative trend A became significantly positive in trend B. Trend A lost the negative significance in Croatia. No joinpoints were observed in Hungary (3.7%), where the trend was significantly positive.



### *RCV-1*

Overall, 24 (88.9%) and 3 (11.1%) countries reported at least one joinpoint and a single trend, respectively (Table 1 and Table 2). An increase in coverage was registered in 12 countries (44.4%), while we observed a decrease in 10 countries (37.1%). In 5 countries (22.2%), no significant variations were observed. Trend B remained significantly positive in Germany, Ireland, Italy, Spain, and Sweden (18.5%), while in Denmark, the significantly negative trend A became significantly positive in trend B. In Austria, Portugal, and Malta (11.1%), the non-significantly trend A (positive in Austria and Portugal; negative in Malta) became significantly positive in trend B. Moreover, in Croatia, the significantly negative trend A became non-significantly positive in trend B (3.7%). Finally, Belgium (3.7%) reported a single significantly positive trend. On the contrary, in Bulgaria, Czechia, Estonia, and Greece, the significantly positive trend A became significantly negative in trend B (14.8%). In Finland, Lithuania, and Poland (11.1%), the non-significantly (positive in Finland and Lithuania; negative in Poland) trend A became significantly negative in trend B. In three countries (Cyprus, France, and Latvia, 11.1%), trend A lost its positive significance, becoming non-significantly positive in Cyprus and France (3.7%) and non-significantly negative in Latvia (3.7%).

### *Analysis by country*

This section describes the national trends in vaccination coverage levels, while also addressing country-specific mandatory vaccination laws. Table 4 describes the trend of vaccination coverage for each indicator at the national level. Only 8 countries (29.6%) (Belgium, Croatia, Denmark, Italy, Malta, Portugal, Slovakia, and Slovenia) reported an increase in vaccination coverage for at least 4 indicators. In particular, Belgium, Malta, and Slovakia showed a significantly positive trend B for four indicators each (HEPB-3, MCV-1, PCV-3, and RCV-1; DTP-3, HEPB-3, MCV-1, RCV-1; DTP-3, HEPB-3, PCV-3, POL-3, respectively) while Denmark showed a significantly positive trend B for all the available indicators (DTP-3, HIB-3, MCV-1, POL-3, PCV-3, RCV-1). Similarly, in Portugal, a significant increase of 5 indicators was observed (DTP-3, HIB-3, MCV-1, POL-3, RCV-1), while in Italy, a significant increase was observed for MCV-1, PCV-3, RCV-1 (a non-significant increase was observed for DTP-3). Finally, in Croatia, trend A lost its negative significance moving to trend B for DTP-3, MCV-1, POL-3 and RCV-1.

On the contrary, 14 countries (51.8%) reported a reduction in vaccination coverage for at least 4 indicators. In particular, in the majority of cases, trend B was significantly negative (Austria, Bulgaria, Cyprus, Estonia, Finland, France, Luxembourg, Netherlands, Poland, Romania, and Sweden), while in Ireland and Germany a mixed situation was observed, with 3 significantly negative trends B and two positive trends A that lost significance, and two significantly negative trends B and

three positive trends A that lost significance, respectively. Also, Lithuania showed a negative general trend, with six indicators showing a reduction (3 significantly negative trends B and 3 positive trends B that lost significance). Trends of specific indicators (significantly negative or positive losing significance) are presented in detail in Table 4.

### *Austria*

Austria's vaccination coverage trends outline a predominantly negative situation. DPT3 saw a switch from a significantly positive yearly increase of 3.65% from 2009 to 2013 to a significantly negative yearly decrease of 1.97% from 2013 to 2020. HEPB3 also saw a similar change from a significantly positive 1.46% yearly increase from 2002 to 2014 to a significantly negative 1.94% yearly decrease from 2014 to 2020. HIB3 also had a similar turn, from a non-significantly positive 3.58% yearly increase from 2009 to 2013 to a significant 1.96% yearly decrease from 2013 to 2020. POL3 is also on this list, where a 2009-2013 significant 3.75% yearly increase turned to a significant 1.98% yearly decrease from 2013 to 2020.

## **Discussion**

Our study analysed the trends of vaccination coverage regarding seven vaccinations in all EU countries from 1980 to 2020 through the joinpoint regression analysis. Overall, we found a downward trend in coverage rates, with most indicators showing a decrease (in 93 cases, 51.7%), while an increase was observed only in 37.8% of cases. This finding was even more evident at the country level: indeed, considering at least four indicators, only Belgium, Croatia, Denmark, Italy, Malta, Portugal, Slovakia, and Slovenia reported an increase, while 14 countries reported a reduction in vaccination coverage.

This decline in vaccination coverage poses significant risks to public health on multiple fronts. The potential consequences of this downward trend are far-reaching and could have severe implications for communities and healthcare systems alike.(29)

With vaccination coverages decreasing, a higher share of the population would be vulnerable to vaccine-preventable communicable diseases. (30)Vaccination programs have been instrumental in curbing the prevalence of such diseases, such as measles, mumps, rubella, pertussis, and polio, which have long plagued humanity.(31) However, with lower immunization rates, the protective shield of herd immunity weakens, rendering susceptible individuals, particularly those who cannot receive vaccines due to medical reasons or those who would not develop a sufficient response to the vaccine despite receiving it (e.g. infants, the elderly, or immunocompromised patients), at a higher risk of

contracting these diseases. As a result, we may witness a resurgence of these illnesses, which were once under control, leading to widespread outbreaks.(30)

Hospital admission rates increase following disease outbreaks (32), increasing the burden on healthcare systems as hospitalization rates surge. This can be expected to place a strain on them, while being already short-staffed and under significant stress from chronic underfinancing. In turn, this can lead to disruption of routine healthcare services, when focus and resources are redirected towards managing the increased burden from vaccine-preventable disease outbreaks, ultimately causing delays and cancellations of non-urgent procedures and appointments and further impacting the quality of care and healthcare services in underserved regions.(33)

For communicable diseases, such as measles, ensuring preventive approaches is the only suitable way, as facing an outbreak in a reactive way has proven to be ineffective.(34) It is therefore crucial to prioritize efforts to improve vaccination coverage rates, but enacting corrective strategies timely requires active monitoring and surveillance systems watching over existing trends.(35)The analysis of coverage trends is a paramount tool of infectious disease surveillance to provide evidence to support policymakers' decisions and pinpoint situations that need to be analysed in terms of underlying causes (17). Indeed, many reasons might explain the prevailing decline in vaccination coverages, including political, scientific, social, and cultural factors that, over the years, have led to an increase in vaccine hesitancy, especially in high-income countries, with a resurgence of vaccine-preventable diseases (8,36,37). Data analysis and summarization is the first step needed to understand these factors, and to provide a useful tool for directing policymakers' choices, increasing healthcare professionals' commitment and sense of responsibility, and fostering the population's involvement with proper communication.

The reduction in coverage in many countries is partly associated to the rise of populist parties, whose politicians have been opposing vaccinations and contributing to the political debate on vaccine mandates that may have eventually led to the increase in vaccine hesitancy (36,38). A study conducted before the COVID-19 pandemic found a highly significant positive association between the percentage of people in a country who voted for populist parties and who believe that vaccines are not effective.(39–42) In this sense, making scientific evidence available is a key task of Public Health professionals to support truly informed and evidence-based decision making (43,44), eventually determining barriers and drivers to vaccination, and using the insight to design evidence-based interventions for improving vaccination uptake, as recommended by the World Health Organization Europe's Tailoring Immunization Programmes document.(45) Thus, a strong scientific leadership that can communicate to the population and influence policy decisions still appears necessary in order

to enable an effective transfer of knowledge and increase vaccination uptake. In this context, the degree of confidence in healthcare professionals is another important factor influencing vaccination uptake (46). Indeed, it is well known how professionals' knowledge and confidence influence patients' choices. Therefore, it is essential to continue monitoring this data and to implement projects, both nationally and internationally (47). In addition, economic, social and educational factors of the population represent important determinants of vaccination attitudes, that impact disproportionately disadvantaged populations. Making vaccines free of charge can have a positive impact on vaccination coverages and overall population health, and is recommended by the WHO Europe in their Targeted Immunization Programmes document. The educational level is related to the acceptance or refusal of vaccination (48–51) and great variability is observed when considering indicators assessing education, economic income and life expectancy (for example the Human Development Index) (52), so that further studies should be conducted in order to assess the correlation between these determinants and the adherence to vaccinations at national level. In this context, our study shows a decline in vaccination, which could be tackled by structuring educational and health promotion activities aimed at the population. Despite the many activities already in place, policymakers should encourage the early implementation of structured courses about vaccination at national and community levels in schools to engage children, parents and teachers, increasing confidence and knowledge in both current and future adults.

Finally, a further point is related to compulsory vaccination. Indeed, six of the eight countries that show predominantly positive trends have instituted some form of compulsory vaccination, whose effect has already been documented (53–55). Of the remaining countries that have made vaccinations compulsory, the effect may not be documented due to the recent introduction of the law (as in the case of France) or, when it affects only a limited number of vaccinations, it doesn't show a general increase of coverage (such as in Greece, where vaccination is recommended with mandatory requirements for school attendance or in Germany, where only the measles vaccination is mandatory, since 2021). However, although mandatory vaccination appears to be an effective measure to fight the decline in coverage, data should be interpreted with caution since it is difficult to assess the impact of other factors (56,57), as discussed above.

Although our study has many strengths, including the systematic collection of data for the trend analysis of vaccination coverage data in all EU countries, and the rigorous and transparent methodology used, we anticipate a number of limitations. Firstly, we considered only the last two trends identified by the joinpoint to classify trends and countries, leaving aside the analysis of the whole time period. Nevertheless, we believe that the last two trends are more informative of the actual

situation. In addition, joinpoints, using only data on yearly vaccination coverages at population level, did not allow us to identify reasons behind identified changes in time trends, thus not allowing changes to be associated with specific factors. Secondly, our study focussed on vaccination trends, thus neglecting absolute values of vaccination coverage rates by themselves: for example, Greece and Sweden showed predominantly negative trends, although they were among the only 6 EU countries having all available coverage indicators  $\geq 95\%$ . However, albeit high vaccination coverage rates, a decline in coverage should always draw attention and the joinpoint analyses allowed us to identify a critical situation. Similarly, the other countries with  $\geq 95\%$  coverages rates showed an overall positive performance, testament to the validity of our approach. Finally, the assessment of countries' performance was based on an arbitrary criterion, although we believe that the choice of  $>50\%$  to define a positive or negative situation can be considered acceptable.

## **Conclusion**

Vaccination coverage in the EU has been declining in the past forty years, except for a few countries. This evidence calls for systemic countermeasures at international, national, and community levels, requiring a huge effort in which public health must play a leading role by providing scientific support to policymakers, communicating effectively, ensuring adequate education, and increasing the knowledge and skills of healthcare professionals on vaccines.

## References

1. World Health Organization (WHO). Immunization, Vaccines and Biologicals [Internet]. [cited 2022 Nov 9]. Available from: <https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases>
2. Greenwood B. The contribution of vaccination to global health: Past, present and future. Vol. 369, Philosophical Transactions of the Royal Society B: Biological Sciences. Royal Society of London; 2014.
3. Fenner F, Arita I, Hendemon DA, JeZek Z, Ladnyi ID. Smallpox and its eradication. WHO. Geneva; 1988.
4. Polio Global Eradication Initiative. GPEI History Project [Internet]. [cited 2022 Nov 9]. Available from: <https://polioeradication.org/>
5. World Health Organization (WHO). Immunization [Internet]. [cited 2022 Nov 9]. Available from: <https://www.who.int/news-room/facts-in-pictures/detail/immunization>
6. World Health Organization Regional Office for Europe. Cost-effectiveness case studies. 2015.
7. Rémy V, Zöllner Y, Heckmann U. Vaccination: the cornerstone of an efficient healthcare system. J Mark Access Health Policy. 2015 Jan;3(1):27041.
8. MacDonald NE, Eskola J, Liang X, Chaudhuri M, Dube E, Gellin B, et al. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161–4.
9. European Centre for Disease Prevention and Control (ECDC). Monthly Measles and Rubella monitoring report - February 2018. 2018.
10. Bozzola E, Spina G, Russo R, Bozzola M, Corsello G, Villani A. Mandatory vaccinations in European countries, undocumented information, false news and the impact on vaccination uptake: The position of the Italian pediatric society. Ital J Pediatr. 2018 Jun 14;44(1).
11. European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler [Internet]. [cited 2022 Nov 9]. Available from: <https://vaccine-schedule.ecdc.europa.eu/>
12. Vanderslott S, Marks T. Charting mandatory childhood vaccination policies worldwide. Vol. 39, Vaccine. Elsevier Ltd; 2021. p. 4054–62.
13. Italian Government. Conversione in legge, con modificazioni, del decreto-legge 7 giugno 2017, n. 73, recante disposizioni urgenti in materia di prevenzione vaccinale. G.U. Serie Generale , n. 182 del 05 agosto 2017 Italy: <https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=60201>;

14. French Ministry of Health. 2019 French Immunisation Schedule. France: <https://www.service-public.fr/particuliers/actualites/A13281>;
15. Identifying reasons for low vaccination coverage - The Public Health Agency of Sweden [Internet]. [cited 2023 Jul 10]. Available from: <https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/vaccinations/identifying-reasons-for-low-vaccination-coverage/>
16. Roush SW. VPD Surveillance Manual Analysis of Surveillance Data: Chapter 20: Analysis of Surveillance Data.
17. Lopalco PL. The role of surveillance in assuring mutual protection for vaccine-preventable diseases. *Clinical Microbiology and Infection*. 2016 Dec 1;22:S85–8.
18. Wang SA, Hyde TB, Mounier-Jack S, Brenzel L, Favin M, Gordon WS, et al. New vaccine introductions: Assessing the impact and the opportunities for immunization and health systems strengthening. Vol. 31, *Vaccine*. 2013.
19. UNICEF Data: Monitoring the situation of children and women. Immunization data [Internet]. [cited 2021 Jul 1]. Available from: <https://immunizationdata.who.int/>
20. World Health Organization (WHO). Immunization dashboard [Internet]. [cited 2021 Jul 1]. Available from: <https://data.unicef.org/resources/dataset/immunization/>
21. UNICEF. [https://data.unicef.org/wp-content/uploads/2016/07/wuenic2021rev\\_web-update.xlsx](https://data.unicef.org/wp-content/uploads/2016/07/wuenic2021rev_web-update.xlsx).
22. World Health Organization (WHO). Indicator Metadata Registry List [Internet]. [cited 2021 Jul 1]. Available from: <https://www.who.int/data/gho/indicator-metadata-registry>
23. Vaccine Scheduler | ECDC [Internet]. [cited 2023 Jul 10]. Available from: <https://vaccine-schedule.ecdc.europa.eu/>
24. Long NP, Huy NT, Thi Huyen Trang N, Luan NT, Anh NH, Nghi TD, et al. Scientific productivity on research in ethical issues over the past half century: A joinpoint regression analysis. *Trop Med Health*. 2014;42(3):121–6.
25. Bosetti C, Bertuccio P, Chatenoud L, Negri E, la Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. *Eur Urol*. 2011;60(1):1–15.
26. Gillis D, Edwards BPM. The utility of joinpoint regression for estimating population parameters given changes in population structure. *Heliyon*. 2019;5(11):e02515.

27. Veljkovic M, Loncarevic G, Kanazir M, Kistic-Tepavcevic D, Gazibara T. Trend in mandatory immunisation coverage: linear and joinpoint regression approach, Serbia, 2000 to 2017. *Eurosurveillance* [Internet]. 2021 Jul 7 [cited 2023 Jul 10];26(26). Available from: [/pmc/articles/PMC8326657/](https://pmc/articles/PMC8326657/)
28. National Cancer Institute. Joinpoint Trend Analysis Software [Internet]. Available from: <https://surveillance.cancer.gov/joinpoint/>
29. Davies SE. Infectious Disease Outbreak Response: Mind the Rights Gap. *Med Law Rev* [Internet]. 2017 May 1 [cited 2023 Jul 11];25(2):270–92. Available from: <https://pubmed.ncbi.nlm.nih.gov/28472502/>
30. Pergam SA, Englund JA, Kamboj M, Gans HA, Young JAH, Hill JA, et al. Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant* [Internet]. 2019 Nov 1 [cited 2023 Jul 11];25(11):e321–30. Available from: <https://pubmed.ncbi.nlm.nih.gov/31394271/>
31. Canoui E, Launay O. [History and principles of vaccination]. *Rev Mal Respir* [Internet]. 2019 Jan 1 [cited 2023 Jul 11];36(1):74–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/30579659/>
32. Hirose M, Gilio AE, Ferronato AE, Ragazzi SLB. The impact of varicella vaccination on varicella-related hospitalization rates: global data review. *Rev Paul Pediatr* [Internet]. 2016 Sep 1 [cited 2023 Jul 10];34(3):359–66. Available from: <https://pubmed.ncbi.nlm.nih.gov/26965075/>
33. Action plan: National workforce capacity to implement the essential public health functions including a focus on emergency preparedness and response [Internet]. [cited 2023 Jul 11]. Available from: <https://www.who.int/publications/i/item/9789240060364>
34. Junghans C, Heffernan C, Valli A, Gibson K. Mass vaccination response to a measles outbreak is not always possible. Lessons from a London prison. *Epidemiol Infect* [Internet]. 2018 Oct 1 [cited 2023 Jul 11];146(13):1689–91. Available from: <https://pubmed.ncbi.nlm.nih.gov/30021664/>
35. Houlihan CF, Whitworth JAG. Outbreak science: recent progress in the detection and response to outbreaks of infectious diseases. *Clin Med (Lond)* [Internet]. 2019 [cited 2023 Jul 11];19(2):140–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/30872298/>
36. Dubé E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. *Expert Rev Vaccines*. 2015 Jan 2;14(1):99–117.



37. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. *PLoS One*. 2018 Dec 1;13(12).
38. Jolley D, Douglas KM. The effects of anti-vaccine conspiracy theories on vaccination intentions. *PLoS One*. 2014 Feb 20;9(2).
39. Hornsey MJ, Finlayson M, Chatwood G, Begeny CT. Donald Trump and vaccination: The effect of political identity, conspiracist ideation and presidential tweets on vaccine hesitancy. *J Exp Soc Psychol*. 2020 May 1;88.
40. Bolsen T, Palm R. Politicization and COVID-19 vaccine resistance in the U.S. In: *Progress in Molecular Biology and Translational Science*. Elsevier B.V.; 2022. p. 81–100.
41. Dahlquist M, Kugelberg HD. Public justification and expert disagreement over non-pharmaceutical interventions for the COVID-19 pandemic. *J Med Ethics*. 2021 Oct 12;medethics-2021-107671.
42. Albrecht D. Vaccination, politics and COVID-19 impacts. *BMC Public Health*. 2022 Dec 1;22(1).
43. Goldstein S, MacDonald NE, Guirguis S, Eskola J, Liang X, Chaudhuri M, et al. Health communication and vaccine hesitancy. *Vaccine*. 2015 Aug 14;33(34):4212–4.
44. Biasio LR, Corsello G, Costantino C, Fara GM, Giammanco G, Signorelli C, et al. Communication about vaccination: A shared responsibility. Vol. 12, *Human Vaccines and Immunotherapeutics*. Taylor and Francis Inc.; 2016. p. 2984–7.
45. Dubé E, Leask J, Wolff B, Hickler B, Balaban V, Hosein E, et al. The WHO Tailoring Immunization Programmes (TIP) approach: Review of implementation to date. *Vaccine*. 2018 Mar 7;36(11):1509–15.
46. Pavlovic D, Sahoo P, Larson HJ, Karafillakis E. Factors influencing healthcare professionals' confidence in vaccination in Europe: a literature review. Vol. 18, *Human Vaccines and Immunotherapeutics*. Taylor and Francis Ltd.; 2022.
47. Figueiredo A de, Eagan RL, Hendrickx G, Karafillakis E, van Damme P, Larson HJ. State of Vaccine Confidence in the European Union 2022 Written by. 2022; Available from: [http://ec.europa.eu/dgs/health\\_food-safety/index\\_en.htm](http://ec.europa.eu/dgs/health_food-safety/index_en.htm)
48. Forshaw J, Gerver SM, Gill M, Cooper E, Manikam L, Ward H. The global effect of maternal education on complete childhood vaccination: A systematic review and meta-analysis. *BMC Infect Dis*. 2017 Dec 28;17(1).

49. Saban M, Myers V, Ben-Shetrit S, Wilf-Miron R. Socioeconomic gradient in COVID-19 vaccination: evidence from Israel. *Int J Equity Health*. 2021 Dec 1;20(1).
50. Herliana P, Douiri A. Determinants of immunisation coverage of children aged 12-59 months in Indonesia: A cross-sectional study. *BMJ Open*. 2017 Dec 1;7(12).
51. Bertoncetto C, Ferro A, Fonzo M, Zanovello S, Napoletano G, Russo F, et al. Socioeconomic determinants in vaccine hesitancy and vaccine refusal in Italy. *Vaccines (Basel)*. 2020 Jun 1;8(2):1–9.
52. The World Bank. World Development Indicators - Human development index [Internet]. [cited 2022 Nov 28]. Available from: <https://databank.worldbank.org/Human-development-index/id/363d401b>
53. Sindoni A, Baccolini V, Adamo G, Massimi A, Migliara G, de Vito C, et al. Effect of the mandatory vaccination law on measles and rubella incidence and vaccination coverage in Italy (2013-2019). *Hum Vaccin Immunother*. 2022;18(1).
54. D'ancona<sup>1</sup> F, D'amario<sup>2</sup> C, Maraglino<sup>2</sup> F, Rezza<sup>1</sup> G, Iannazzo<sup>2</sup> S. The law on compulsory vaccination in Italy: an update 2 years after the introduction. :1. Available from: [www.eurosurveillance.org](http://www.eurosurveillance.org)
55. Lee C, Robinson JL. Systematic review of the effect of immunization mandates on uptake of routine childhood immunizations. *Journal of Infection*. 2016 Jun 1;72(6):659–66.
56. Rezza G. Mandatory vaccination for infants and children: the Italian experience. Vol. 113, *Pathogens and Global Health*. Taylor and Francis Ltd.; 2019. p. 291–6.
57. Odone A, Dallagiaco G, Frascella B, Signorelli C, Leask J. Current understandings of the impact of mandatory vaccination laws in Europe. *Expert Rev Vaccines*. 2021;20(5):559–75.

**Box 1.** Abbreviations used for vaccination antigens.

DTP-3	percentage of one-year-olds who had received all the three doses of the combined diphtheria, tetanus toxoid, and pertussis vaccine
HEPB-3	percentage of one-year-olds who had received three doses of hepatitis B vaccine
HIB-3	percentage of one-year-olds who had received three doses of Haemophilus influenzae type B vaccine
MCV-1	percentage of one-year-olds who had received the first dose of measles-containing vaccine
PCV-3	percentage of one-year-olds who had received three doses of pneumococcal conjugate vaccine
POL-3	percentage of one-year-olds who had received three doses of polio vaccine
RCV-1	percentage of one-year-olds who had received at least one dose of rubella-containing vaccine.

**Box 2.** Abbreviations used for countries

Country Abbreviation	Country Name	Country Abbreviation	Country Name
AT	Austria	HU	Hungary
BE	Belgium	IE	Ireland
BG	Bulgaria	IT	Italy
CY	Cyprus	LT	Lithuania
CZ	Czech Republic	LU	Luxembourg
DE	Germany	LV	Latvia
DK	Denmark	MT	Malta
EE	Estonia	NL	Netherlands
EL	Greece	PL	Poland
ES	Spain	PT	Portugal
FI	Finland	RO	Romania
FR	France	SE	Sweden
HR	Croatia	SI	Slovenia

HU	Hungary	SK	Slovakia
IE	Ireland		

**Table 1.** Trend A and trend B across coverage indicators for seven vaccinations (DTP-3, HEPB-3, HIB-3, MCV-1, PCV-3, POL-3, RCV-1) across 27 EU countries

Trend A	Trend B			
	Significant increase (n = 39)	Significant decrease (n = 49)	Non-significant increase (n = 39)	Non-significant decrease (n = 17)
Significant increase	DTP-3: PT, SK HEPB-3: BE, DE, PL HIB-3: EE, EL, PL, PT MCV-1: IE, IT, ES, LU, SE PCV-3: IT POL-3: CY, PT RCV-1: DE, IE, IT, ES, SE <b>N = 22</b>	DTP-3: AT, PL, RO, SI HEPB-3: AT, IE, LV, LT HIB-3: HR, DE, IE, IT, NL, SK, SE MCV-1: BG, CZ, EE, PL, RO PCV-3: BG, DE, IE, SE POL-3: AT, EE, FR, RO, SI, SE RCV-1: CZ, BG, EE, EL <b>N = 34</b>	DTP-3: CY, FR, IE, LU HEPB-3: CY, FR, EL, NL, PT, SE HIB-3: BE, CY, LV, LT MCV-1: CY, FR, DE PCV-3: LU POL-3: EL RCV-1: CY, FR <b>N = 21</b>	DTP-3: DE, LT HEPB-3: LU, ES HIB-3: FR, MT, ES MCV-1: - PCV-3: - POL-3: BE, DE, IE, LT, LU, MT, ES RCV-1: LV <b>N = 15</b>
Significant decrease	DTP-3: DK HEPB-3: CZ, SK HIB-3: DK MCV-1: DK, LV PCV-3: SK POL-3: CZ, DK, SK RCV-1: DK <b>N = 11</b>	DTP-3: - HEPB-3: - HIB-3: - MCV-1: - PCV-3: - POL-3: PL RCV-1: - <b>N = 1</b>	DTP-3: HR, CZ, FI HEPB-3: - HIB-3: FI, SI MCV-1: HR PCV-3: - POL-3: HR RCV-1: HR <b>N = 8</b>	DTP-3: - HEPB-3: - HIB-3: - MCV-1: - PCV-3: - POL-3: - RCV-1: - <b>N = 0</b>

Non-significant increase	DTP-3: - HEPB-3: - HIB-3: - MCV-1: PT PCV-3: - POL-3: - RCV-1: AT, PT <b>N = 3</b>	DTP-3: EE, NL, SE HEPB-3: HR, RO HIB-3: AT MCV-1: FI, LT PCV-3: - POL-3: FI, IT, NL RCV-1: FI, LT <b>N = 13</b>	DTP-3: BE, LV HEPB-3: - HIB-3: - MCV-1: - PCV-3: EL POL-3: - RCV-1: - <b>N = 3</b>	DTP-3: - HEPB-3: - HIB-3: LU MCV-1: - PCV-3: - POL-3: - RCV-1: LU <b>N = 2</b>
Non-significant decrease	DTP-3: - HEPB-3: - HIB-3: - MCV-1: AT, MT PCV-3: - POL-3: - RCV-1: MT <b>N = 3</b>	DTP-3: - HEPB-3: - HIB-3: - MCV-1: - PCV-3: - POL-3: - RCV-1: PL <b>N = 1</b>	DTP-3: - HEPB-3: IT HIB-3: CZ MCV-1: NL, SK PCV-3: - POL-3: - RCV-1: NL, RO, SK <b>N = 7</b>	DTP-3: - HEPB-3: - HIB-3: - MCV-1: - PCV-3: - POL-3: - RCV-1: - <b>N = 0</b>

Trend A: the second-last trend in each time series considered; Trend B: the last trend in each time series considered.

**Table 2.** Coverage indicator trends for seven vaccinations (DTP-3, HEPB-3, HIB-3, MCV-1, PCV-3, POL-3, RCV-1) without any joinpoint

	DTP-3	HEPB-3	HIB-3	MCV-1	PCV-3	POL-3	RCV-1
Significant increase (n = 13)	EL, MT, ES	MT	-	BE, EL	BE, DK, HU, FR, SI	HU	BE
Significant decrease (n = 5)	BG	EE	-	-	FI, NL	BG	-
Non-significant increase (n = 8)	IT	BG	-	SI	LT, LV, PT	LV	SI
Non-significant decrease (n = 3)	-	-	BG, RO	-	RO	-	-
No change (n = 7)	HU	-	HU	HU	CY, ES, PL	-	HU

**Table 3.** Overall performance of the coverage trends for seven vaccinations (DTP-3, HEPB-3, HIB-3, MCV-1, PCV-3, POL-3, RCV-1) across 27 EU countries

Type of trend	N	%	% out of 180 regressions
Positive significance (ps)	52	27.5	28.9
Loss of negative significance (lns)	16	8.5	8.9
<b>General positive trend*</b>	<b>68</b>	<b>36.0</b>	<b>37.8</b>
Loss of positive significance (lps)	39	20.6	21.7
Negative significance (ns)	54	28.6	30
<b>General negative trend*</b>	<b>93</b>	<b>49.2</b>	<b>51.7</b>
No change (nc)	19	10.1	10.6
Data not available (na)	9	4.8	-
Total	189	100	-

\*General positive trend refers to the sum of “significantly positive trend” and “loss of negative significance”. General negative trend refers to the sum of “significantly negative trend” and “loss of positive significance”.



**Table 4.** Trend of vaccination coverage at national level

Country	Indicator							Overall negative/positive score (>50% indicators are negative/positive, respectively – 4 out of 7)
	DTP-3	HEPB-3	HIB-3	MCV-1	PCV-3	POL-3	RCV-1	
Austria	ns	ns	ns	ps	na	ns	ps	Negative
Belgium	nc	ps	lps	ps	ps	lps	ps	Positive
Bulgaria	ns	lns	lps	ns	ns	ns	ns	Negative
Croatia	lns	ns	ns	lns	na	lns	lns	Positive
Cyprus	lps	lps	lps	lps	nc	ps	lps	Negative
Czechia	lns	ps	nc	ns	na	ps	ns	-
Denmark	ps	na	ps	ps	ps	ps	ps	Positive
Estonia	ns	ns	ps	ns	na	ns	ns	Negative
Finland	lns	na	lns	ns	ns	ns	ns	Negative
France	lps	lps	lps	lps	ps	ns	lps	Negative

Germany	lps	ps	ns	lps	ns	lps	ps	Negative
Greece	ps	lps	ps	ps	nc	lps	ns	-
Hungary	nc	na	nc	nc	ps	ps	nc	-
Ireland	lps	ns	ns	ps	ns	lps	ps	Negative
Italy	lps	nc	ns	ps	ps	ns	ps	Positive
Latvia	nc	ns	lps	ps	lps	lps	lps	-
Lithuania	lps	ns	lps	ns	lps	lps		Negative
Luxembourg	lps	lps	nc	ps	lps	lps	nc	Negative
Malta	ps	ps	lps	ps	na	lps	ps	Positive
Netherlands	ns	lps	ns	nc	ns	ns	nc	Negative
Poland	ns	ps	ps	ns	nc	ns	ns	Negative
Portugal	ps	lps	ps	ps	lps	ps	ps	Positive

Romania	ns	ns	lps	ns	lps	ns	nc	Negative
Slovakia	ps	ps	ns	nc	ps	ps	nc	Positive
Slovenia	ns	na	lns	lns	ps	ns	lns	Positive
Spain	ps	lps	lps	ps	nc	lps	ps	-
Sweden	ns	lps	ns	ps	ns	ns	ps	Negative

Positive significance: ps

Loss of negative significance: lns


Loss of positive significance: lps

Negative significance: ns

No change: nc


Data not available: na

**Figure 1.** Trend of seven vaccination coverage (DTP-3, HEPB-3, Hib-3, MCV-1, PCV-3, POL-3, RCV-1) across 27 EU countries




**Figure xxx.** Vaccination coverage trends, by country

### Austria




- DTP3 - 5 Joinspoints
  - 1980-1996 APC = 0,07
  - 1996-1999 APC = -5,26\*
  - 1999-2002 APC = 3,18\*
  - 2002-2009 APC = -0,25
  - 2009-2013 APC = 3,65\*
  - 2013-2020 APC = -1,97\*
- ▲ HIB3 - 3 Joinspoints
  - 1999-2003 APC = 4,17\*
  - 2003-2009 APC = -0,09
  - 2009-2013 APC = 3,58
  - 2013-2020 APC = -1,96\*
- + POL3 - 5 Joinspoints
  - 1980-1997 APC = 0,19\*
  - 1997-2000 APC = -6,93\*
  - 2000-2003 APC = 4,77\*
  - 2003-2009 APC = -0,48
  - 2009-2013 APC = 3,75\*
  - 2013-2020 APC = -1,98\*
- \* MCV1 - 5 Joinspoints
  - 1981-1983 APC = -3,39
  - 1983-1986 APC = 35,47\*
  - 1986-1994 APC = 0,24
  - 1994-1997 APC = 13,12\*
  - 1997-2000 APC = -5,97
  - 2000-2020 APC = 1,58\*
- \* HEPB3 - 2 Joinspoints
  - 2000-2002 APC = 59,24\*
  - 2002-2014 APC = 1,46\*
  - 2014-2020 APC = -1,94\*
- ♦ RCV1 - 5 Joinspoints
  - 1981-1983 APC = -3,39
  - 1983-1986 APC = 35,47\*
  - 1986-1994 APC = 0,24
  - 1994-1997 APC = 13,12\*
  - 1997-2000 APC = -5,97
  - 2000-2020 APC = 1,58\*

### Belgium




### Bulgaria







### Croatia




### Cyprus




### Czechia




### Denmark




### Estonia




### Finland



### France




### Germany







### Greece




### Hungary




### Ireland




### Italy




### Latvia



### Lithuania




### Luxembourg









### Malta



### Netherlands




### Poland



- DTP3 - 5 Joinpoints
- 1980-1985 APC = -0,37\*
- 1985-1988 APC = 0,69\*
- 1988-1993 APC = -0,31\*
- 1993-1997 APC = 0,84\*
- 1997-2013 APC = 0,08\*
- 2013-2019 APC = -0,77\*
- ▲ HIB3 - 1 Joinpoint
- 2005-2007 APC = 121,26\*
- 2007-2019 APC = 0,56
- ✦ POL3 - 4 Joinpoints
- 1980-1994 APC = -0,03
- 1994-1997 APC = 1,02
- 1997-2006 APC = 0,08
- 2006-2014 APC = -0,60\*
- 2014-2019 APC = -1,61\*
- ✖ MCV1 - 1 Joinpoint
- 1980-2011 APC = 0,22\*
- 2011-2019 APC = -0,80\*
- ✧ HEPB3 - 2 Joinpoints
- 1991-1993 APC = -1,33
- 1993-1996 APC = 354,43\*
- 1996-2019 APC = 0,27
- ◆ PCV3 - 0 Joinpoints
- 2018-2019 APC = 0,00
- ✧ RCV1 - 2 Joinpoints
- 1988-2006 APC = 0,21\*
- 2006-2013 APC = -0,05
- 2013-2019 APC = -0,92\*


### Portugal




- DTP3 - 3 Joinpoints
- 1980-1982 APC = 4,28\*
- 1982-1985 APC = -1,63
- 1985-1991 APC = 3,85
- 1991-2019 APC = 0,16
- ▲ HIB3 - 2 Joinpoints
- 1998-2000 APC = -4,54\*
- 2000-2003 APC = 3,47\*
- 2003-2019 APC = 0,17\*
- ◊ POL3 - 2 Joinpoints
- 1980-1984 APC = 5,64
- 1984-1987 APC = 63,83\*
- 1987-2019 APC = 0,28\*
- ✱ MCV1 - 3 Joinpoints
- 1980-1983 APC = -5,27\*
- 1983-1986 APC = 19,26\*
- 1986-1989 APC = 6,62
- 1989-2019 APC = 0,21
- ✱ HEPB3 - 2 Joinpoints
- 1995-1997 APC = 172,35\*
- 1997-2005 APC = 6,87\*
- 2005-2019 APC = 0,12
- PCV3 - 0 Joinpoints
- 2016-2019 APC = 9,46
- ✱ RCV1 - 2 Joinpoints
- 1984-1986 APC = 23,68\*
- 1986-1989 APC = 5,91
- 1989-2019 APC = 0,22




### Romania



### Slovakia




### Slovenia






### Spain



### Sweden



**Supplementary Material – Table S1. Annual Percent Change (APC) in vaccination coverage in EU Countries from 1980 to 2020**

Country	DTP-3	HEPB-3	HIB-3	MCV-1	PCV-3	POL-3	RCV-1
Austria (AT)	1980-1996	2000-2002	1999-2003	1981-1983	-	1980-1997	1981-1983
	0.07	59.24*	4.17*	-3.39		0.19*	-3.39
	90%	81%	84%	25%		95%	25%
	1996-1999	2002-2014	2003-2009	1983-1986		1997-2000	1983-1986
	-5.26*	1.46*	-0.09	35.47*		-6.93*	35.47*
	74%	98%	83%	60%		71%	60%
	1999-2002	2014-2020	2009-2013	1986-1994		2000-2003	1986-1994
	3.18	-1.94*	3.58	0.24		4.77	0.24
	83%	85%	95%	60%		84%	60%
	2002-2009		2013-2020	1994-1997		2003-2009	1994-1997
	-0.25		-1.96*	13.12*		-0.48	13.12*
	83%		85%	90%		83%	90%
	2009-2013			1997-2000		2009-2013	1997-2000
	3.65*			-5.97		3.75*	-5.97
95%			75%		95%	75%	
2013-2020			2000-2020		2013-2020	2000-2020	
-1.97*			1.58*		-1.98*	1.58*	
85%			94%		85%	94%	
Belgium (BE)	1980-1995	1997-1999	1993-1997	1981-2019	2012-2019	1980-1982	1985-2019
	0.04	365.03*	-17.89*	1.18*	0.19*	-5.19*	0.98*
	94%	46%	6%	96%	94%	90%	96%

	1995-1998	1999-2019	1997-2000			1982-1986	
	-4.44	2.74*	120.62*			1.91*	
	79%	97%	86%			99%	
	1998-2001		2000-2019			1986-1994	
	5.43		0.14			-0.68*	
	95%		97%			93%	
	2001-2019					1994-2007	
	0.15					0.49*	
	98%					99%	
						2007-2019	
						-0.03	
						98%	
Bulgaria (BG)	1980-2020	1992-2020	2010-2020	1980-1990	2010-2012	1980-2020	1993-2009
	-0.21*	0.15	-0.17	0.38	14.89*	-0.18*	0.31*
	91%	91%	91%	99%	94%	91%	96%
				1990-1993	2012-2020		2009-2020
				-2.85	-1.50*		-0.49*
				88%	85%		88%
				1993-2009			
				0.33*			
				96%			
				2009-2020			
				-0.50*			
				88%			

Croatia (HR)	1992-1996	2007-2009	2002-2004	1992-2010	-	1992-1997	1992-2010
	2.47*	1.55	9.23*	0.42*		1.74*	0.42*
	91%	97%	95%	96%		92%	96%
	1996-2005	2009-2019	2004-2019	2010-2017		1997-2005	2010-2017
	0.53*	-0.58*	-0.28*	-1.05*		0.51*	-1.05*
	96%	93%	94%	89%		96%	89%
	2005-2013			2017-2019		2005-2013	2017-2019
	0.02			1.95		-0.01	1.95
	96%			93%		96%	93%
	2013-2017					2013-2017	
	-1.11*					-1.03*	
	92%					92%	
2017-2019					2017-2019		
1.10					1.18		
94%					94%		
<hr/>							
Cyprus (CY)	1980-1983	1991-1993	2000-2007	1980-1983	2015-2019	1980-1983	1980-1983
	-13.21*	44.20*	18.53*	-15.04*	0.00	-9.88*	-15.04*
	34%	41%	90%	19%	81%	36%	19%
	1983-1986	1993-1996	2007-2019	1983-1987		1983-1986	1983-1987
	49.60*	29.60*	0.19	46.87*		48.35*	46.87*
	91%	88%	92%	91%		91%	91%
	1986-2019	1996-2004		1987-1990		1986-2019	1987-1990
	0.25	-0.06		-4.76		0.23*	-4.76
	96%	88%		77%		96%	77%
		2004-2009		1990-1996			1990-1996

		1.73*		2.59*		2.59*	
		96%		90%		90%	
		2009-2019		1996-2019		1996-2019	
		0.03		0.04		0.04	
		94%		86%		86%	
Czech Republic (CZ)	1993-1995	2002-2004	2002-2008	1993-2016	-	1993-2005	1993-2016
	-1.45*	7.02*	0.55*	0.11*		-0.17*	0.11*
	96%	98%	99%	98%		96%	98%
	1995-1998	2004-2014	2008-2014	2016-2019		2005-2008	2016-2019
	0.70	0.06	-0.02	-1.98*		0.99	-1.98*
	98%	99%	99%	92%		99%	92%
	1998-2003	2014-2017	2014-2017			2008-2014	
	-0.19	-1.69*	-1.62			-0.08	
	97%	94%	94%			99%	
	2003-2011	2019-2019	2017-2019			2014-2017	
	0.25*	1.58*	1.56			-1.58*	
	99%	97%	97%			94%	
	2011-2016					2017-2019	
	-0.70*					1.54*	
	96%					97%	
	2016-2019						
	0.38						
	97%						
Denmark (DK)	1980-1996	-	1993-1998	1987-2003	2009-2020	1980-2003	1987-2003

	-0.07		3.96*	1.39*	1.00*	-0.01	1.39*
	77%		97%	96%	96%	96%	96%
	1996-1999		1998-2008	2003-2009		2003-2007	2003-2009
	4.84*		-0.94*	-2.19*		-2.52*	-2.19*
	99%		88%	84%		87%	84%
	1999-2008		2008-2020	2009-2020		2007-2020	2009-2020
	-1.38*		0.78*	1.21*		0.82*	1.21*
	88%		97%	94%		97%	94%
	2008-2020						
	0.85*						
	97%						
<hr/>							
Estonia (EE)	1993-1996	2004-2020	2004-2006	1993-1997	-	1993-1996	1993-1997
	6.49*	-0.19*	94.68*	4.90*		8.02*	4.90*
	87%	90%	88%	88%		86%	88%
	1996-2001		2006-2020	1997-2004		1996-2003	1997-2004
	1.60*		0.18*	1.27*		1.56*	1.27*
	94%		91%	96%		95%	96%
	2001-2006			2004-2020		2003-2020	2004-2020
	0.37			-0.49*		-0.28*	-0.49*
	95%			91%		91%	91%
	2006-2020						
	-0.31*						
	91%						
<hr/>							
Finland (FI)	1980-1984	-	1992-1994	1981-1983	2010-2020	1980-1983	1981-1983

	1.03*		-1.51	6.82*	-0.59*	-5.31*	6.82*
	95%		93%	81%	89%	78%	81%
1987-1990		1994-2014		1983-1988		1983-1986	1983-1988
	-2.63*		0.24*	3.62*		7.21	3.62*
	90%		98%	98%		95%	98%
1990-1993		2014-2017		1988-1994		1986-2013	1988-1994
	3.00*		-3.35*	0.65*		0.10	0.65*
	99%		89%	99%		98%	99%
1993-2014		2017-2020		1994-1998		2013-2020	1994-1998
	-0.04		0.69	-0.92		-1.36*	-0.92
	98%		91%	96%		91%	96%
2014-2017				1998-2009			1998-2009
	-2.97*			0.18			0.18
	89%			98%			98%
2017-2020				2009-2020			2009-2020
	0.60			-0.27*			-0.27*
	91%			96%			96%
<hr/>							
France (FR)	1980-1985	1980-2003	1998-2006	1983-1985	2010-2019	1980-1985	1983-1985
	4.68*	2.48	2.50*	49.59*	0.50*	5.09*	49.59*
	95%	28%	97%	35%	92%	97%	35%
1985-1988		2003-2013	2006-2019	1985-1991		1985-1988	1985-1991
	-4.78*	11.41*	-0.22	13.83*		-6.50*	13.83*
	79%	82%	95%	74%		81%	74%
1988-1991		2013-2019		1991-2004		1988-1991	1991-2004
	4.58*	1.46		1.10*		5.31*	1.10*



	94%	91%		88%		95%	88%
	1991-2019			2004-2019		1991-2011	2004-2019
	0.06			0.18		0.17*	0.18
	96%			90%		99%	90%
						2011-2019	
						-0.49*	
						96%	
Germany (DE)	1981-1993	1993-1995	1991-1993	1980-1982	2008-2010	1980-1982	1991-1994
	-2.49*	72.49*	15.15*	32.45*	10.39*	7.93*	7.65*
	62%	45%	80%	50%	85%	95%	90%
	1993-1999	1995-1998	1993-2000	1982-1994	2010-2019	1982-1990	1994-2019
	4.77*	21.11*	2.11*	5.12*	-0.37*	-2.82*	0.29*
	97%	81%	94%	90%	84%	80%	97%
	1999-2019	1998-2019	2000-2019	1994-2019		1990-1994	
	-0.08	0.17*	-0.13*	0.30		5.72*	
	93%	87%	92%	97%		95%	
						1994-2019	
						-0.10	
						93%	

Greece (EL)	1980-2020	1991-1994	1994-1996	1984-2020	2012-2014	1980-1988	1995-1997
	1.00*	-41.81*	427.34*	1.21*	82.79	0.91*	9.84*
	99%	2%	36%	97%	96%	98%	90%
		1994-1998	1996-2020		2014-2020	1988-1991	1997-2009
		145.82*	1.90*		2.18	-5.29*	0.92*
		69%	99%		96%	77%	99%
		1998-2020				1991-1994	2009-2020
		0.36				5.11*	-0.27*
		96%				95%	97%
						1994-1999	
					-2.20*		
					87%		
					1999-2007		
					1.46*		
					99%		
					2007-2020		
					0.00		
					99%		
<hr/>							
Hungary (HU)	1980-2019	-	1999-2019	1980-2019	2011-2019	1980-2019	1989-2019
	0.00*		-0.00*	0.00*	1.92*	0.01*	0.00
	99%		99%	99%	99%	99%	99%
<hr/>							
Ireland (IE)	1980-1984	2010-2018	1997-1999	1983-1986	2010-2012	1980-1996	1983-1986
	7.55*	1.11*	6.10*	104.07*	40.94*	0.16	104.07*
	45%	95%	86%	65%	91%	77%	65%

	1984-1987	2018-2020	1999-2002	1986-2020	2012-2020	1996-2010	1986-2020
	-2.78	-27.59*	-1.39*	0.82*	-1.62*	1.32*	0.82*
	44%	46%	83%	92%	86%	94%	92%
	1987-1990		2002-2005			2010-2020	
	16.24*		2.96*			-0.12	
	65%		90%			94%	
	1990-2006		2005-2013				
	2.14*		0.67*				
	91%		95%				
	2006-2020		2013-2020				
	0.14		-0.29*				
	94%		94%				
Italy (IT)	1990-2020	1991-2012	2000-2002	1990-1998	2008-2013	1983-1989	1990-1998
	0.11	0.08*	23.79*	3.22*	7.50*	-1.84*	3.22*
	94%	96%	83%	55%	87%	75%	55%
		2012-2015	2002-2005	1998-2002	2013-2020	1989-1992	1998-2002
		-1.00	4.26*	10.11*	0.75*	5.96	10.11*
		93%	95%	81%	91%	97%	81%
		2015-2020	2005-2020	2002-2020		1992-2020	2002-2020
		0.27	-0.20*	0.39*		-0.17*	0.39*
		94%	94%	92%		94%	92%
Latvia (LV)	1992-1995	1998-2000	1994-1997	1992-1994	2011-2020	1992-2020	1993-1997
	4.36	169.35*	69.56*	-8.19*	2.77	0.10	5.73*

	98%	95%	67%	81%	91%	99%	97%
	1995-2020	2000-2020	1997-2020	1994-1997			1997-2020
	0.02	-0.56*	1.40	8.46*			-0.07
	99%	99%	99%	97%			99%
				1997-2012			
				-0.43*			
				90%			
				2012-2020			
				0.75*			
				99%			
Lithuania (LT)	1992-1998	1998-2000	1999-2002	1992-1996	2016-2020	1992-2008	1992-1996
	2.98*	12.23*	36.43*	1.74*	0.24	0.50*	1.74*
	93%	98%	5%	96%	83%	96%	96%
	1998-2020	2000-2020	2002-2005	1996-2003		2008-2020	1996-2003
	-0.10	-0.25*	164.84*	0.28		-0.35	0.28
	91%	91%	61%	98%		91%	98%
			2005-2020	2003-2009			2003-2009
			0.75	-0.25			-0.25
			91%	96%			96%
				2009-2012			2009-2012
				-1.23			-1.23
				93%			93%
				2012-2017			2012-2017
				0.23			0.23
				94%			94%

				2017-2020			2017-2020
				-1.25*			-1.25*
				90%			90%
Luxembourg (LU)	1983-1987	1997-2002	1997-2002	1983-1986	2008-2013	1983-1992	1995-2001
	6.46*	13.13*	2.70*	21.76*	2.36*	0.00	0.93*
	95%	95%	98%	68%	95%	90%	94%
	1987-1998	2002-2020	2002-2005	1986-1997	2013-2020	1992-1996	2001-2010
	0.88*	-0.00	-0.11	2.38*	0.28	2.18*	0.23*
	98%	96%	98%	91%	96%	98%	96%
	1998-2020		2005-2008	1997-2020		1996-2005	2010-2013
	0.03		0.39	0.36*		0.13	1.01
	99%		99%	99%		99%	99%
			2008-2020			2005-2009	2013-2020
			-0.00			-1.06*	-0.02
			99%			96%	99%
						2009-2013	
						1.02*	
						99%	
						2013-2020	
						-0.01	
						99%	
Malta (MT)	1996-2020	2003-2020	1996-1998	1984-1987	-	1981-2005	1985-1987
	1.68*	0.95*	54.81*	85.33*		0.74*	118.89*
	98%	98%	89%	59%		94%	59%

			1998-2009	1987-1992		2005-2008	1987-1992
			-2.31*	14.17		-10.33	11.99
			73%	92%		72%	92%
			2009-2012	1992-1995		2008-2012	1992-1995
			11.20*	-15.77		9.64*	-15.11
			99%	51%		99%	51%
			2012-2020	1995-2020		2012-2020	1995-2020
			-0.34	2.23*		-0.19	2.23*
			98%	95%		98%	95%
Netherlands (NL)	1980-2012	2011-2014	1997-2012	1980-1997	2009-2019	1980-2012	1980-1997
	0.01	77.36*	0.09*	0.28*	-0.40*	0.01	0.28*
	97%	94%	97%	96%	93%	97%	96%
	2012-2019	2014-2019	2012-2019	1997-2014		2012-2019	1997-2014
	-0.59*	0.98	-0.59*	0.02		-0.59*	0.02
	94%	92%	94%	96%		94%	96%
				2014-2017			2014-2017
				-1.10			-1.10
				93%			93%
				2017-2019			2017-2019
				0.50			0.50
				94%			94%
Poland (PL)	1980-1985	1991-1993	2005-2007	1980-2011	2018-2019	1980-1994	1988-2006
	-0.37*	-1.33	121.26*	0.22*	0.00	-0.03	0.21*
	94%	1%	88%	98%	60%	95%	99%

	1985-1988	1993-1996	2007-2019	2011-2019		1994-1997	2006-2013
	0.69	354.43*	0.56*	-0.80*		1.02	-0.05
	96%	56%	95%	93%		98%	98%
	1988-1993	1996-2019				1997-2006	2013-2019
	-0.31	0.27*				0.08	-0.92*
	95%	91%				99%	93%
	1993-1997					2006-2014	
	0.84*					-0.60*	
	98%					94%	
	1997-2013					2014-2019	
	0.08*					-1.61*	
	99%					87%	
	2013-2019						
	-0.77*						
	95%						
Portugal (PT)	1980-1982	1995-1997	1998-2000	1980-1983	2016-2019	1980-1984	1984-1986
	4.28	172.35*	-4.54*	-5.27*	9.46	5.64*	23.68*
	78%	49%	86%	48%	98%	21%	75%
	1982-1985	1997-2005	2000-2003	1983-1986		1984-1987	1986-1989
	-1.63	6.87*	3.47*	19.26*		63.83*	5.91
	72%	94%	99%	75%		81%	96%
	1985-1991	2005-2019	2003-2019	1986-1989		1987-2019	1989-2019
	3.85*	0.12	0.17*	6.62		0.28*	0.22*
	96%	98%	99%	96%		99%	99%
	1991-2019			1989-2019			

	0.16*			0.21*			
	99%			99%			
Romania (RO)	1985-2002	1996-2012	2011-2020	1983-2001	2019-2020	1985-2002	2002-2012
	0.37*	-0.15*	-0.65	1.00*	-3.41	0.58*	-0.38
	98%	96%	87%	98%	85%	98%	94%
	2002-2020	2012-2015		2001-2020		2002-2020	2012-2015
	-0.81*	-2.24		-0.72*		-0.82*	-2.89
	87%	90%		87%		87%	86%
		2015-2018					2015-2020
		0.79					0.63
		93%					87%
		2018-2020					
		-3.07*					
		87%					
Slovakia (SK)	1994-2012	2000-2002	1996-1998	1994-2012	2009-2012	1994-2012	1994-2012
	0.00*	0.44	223.49*	0.01	-0.05*	0.07*	0.01
	99%	99%	36%	99%	99%	99%	99%
	2012-2015	2002-2012	1998-2003	2012-2015	2012-2015	2012-2015	2012-2015
	-1.03*	-0.00	16.81*	-1.16	-1.07*	-1.16*	-1.16
	96%	99%	99%	95%	96%	96%	95%
	2015-2018	2012-2015	2003-2020	2015-2020	2015-2020	2015-2020	2015-2020
	0.05*	-1.08*	-0.19*	0.17	0.07*	0.23*	0.17
	96%	96%	97%	96%	96%	97%	96%
	2018-2020	2015-2020					



	0.55*	0.22*					
	97%	97%					
Slovenia (SI)	1992-1995	-	2001-2007	1992-2020	2015-2020	1992-1995	1992-2020
	0.43		0.77*	0.13	8.08*	0.25	0.13
	98%		97%	94%	70%	98%	94%
	1995-1998		2007-2018			1995-1998	
	-2.81*		-0.33*			-2.60*	
	91%		93%			90%	
	1998-2007		2018-2020			1998-2007	
	0.69*		0.88			0.68*	
	97%		95%			97%	
	2007-2020					2007-2020	
	-0.23*					-0.24*	
	95%					95%	
Spain (ES)	1984-2020	1996-2002	1998-2001	1981-1984	2017-2020	1984-1986	1981-1984
	0.39*	-0.41	6.48*	106.35*	-0.00	-7.98*	106.35*
	98%	82%	96%	68%	88%	75%	68%
		2002-2005	2001-2020	1984-2020		1986-1989	1984-2020
		6.57*	-0.02	0.49*		9.95*	0.49*
		96%	98%	98%		94%	98%
		2005-2020				1989-1992	
		-0.07				-4.47*	
		98%				85%	
						1992-2000	

						1.60*	
						95%	
						2000-2020	
						-0.02	
						98%	
Sweden (SE)	1980-1999	2011-2018	1991-1993	1980-1983	2008-2010	1980-1991	1982-1996
	0.00	19.55*	29.79*	1.63*	23.45*	0.18*	0.39*
	99%	92%	99%	93%	98%	99%	96%
	1999-2020	2018-2020	1993-2020	1983-1996	2010-2020	1991-2020	1996-1999
	-0.09*	3.80	-0.13*	0.34*	-0.50*	-0.07*	-2.63*
	97%	97%	97%	96%	97%	97%	89%
				1996-1999			1999-2003
				-2.55*			1.61*
				89%			95%
				1999-2003			2003-2020
				1.60*			0.08*
				95%			97%
				2003-2020			
				0.08*			
				97%			

\* APC is significantly different from zero at alpha = 0.05

DTP-3: percentage of one-year-olds who had received all the three doses of the combined diphtheria, tetanus toxoid, and pertussis vaccine

HEPB-3: percentage of one-year-olds who had received three doses of hepatitis B vaccine

HIB-3: percentage of one-year-olds who had received three doses of *Haemophilus influenzae* type B vaccine

MCV-1: percentage of one-year-olds who had received the first dose of measles-containing vaccine

PCV-3: percentage of one-year-olds who had received three doses of pneumococcal conjugate vaccine

POL-3: percentage of one-year-olds who had received three doses of polio vaccine

RCV-1: percentage of one-year-olds who had received at least one dose of rubella-containing vaccine.